vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and LiveRamp Holdings, Inc. (RAMP). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $212.2M, roughly 1.3× LiveRamp Holdings, Inc.). LiveRamp Holdings, Inc. runs the higher net margin — 18.8% vs -45.7%, a 64.5% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 8.6%). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 11.1%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
LiveRamp Holdings, Inc., is an American SaaS company that offers a data connectivity platform whose services include data onboarding, the transfer of offline data online for marketing purposes.
GH vs RAMP — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $212.2M |
| Net Profit | $-128.5M | $39.9M |
| Gross Margin | 64.6% | 71.9% |
| Operating Margin | -43.0% | 18.6% |
| Net Margin | -45.7% | 18.8% |
| Revenue YoY | 39.4% | 8.6% |
| Net Profit YoY | -15.8% | 255.7% |
| EPS (diluted) | $-1.01 | $0.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $212.2M | ||
| Q3 25 | $265.2M | $199.8M | ||
| Q2 25 | $232.1M | $194.8M | ||
| Q1 25 | $203.5M | $188.7M | ||
| Q4 24 | $201.8M | $195.4M | ||
| Q3 24 | $191.5M | $185.5M | ||
| Q2 24 | $177.2M | $176.0M | ||
| Q1 24 | $168.5M | $171.9M |
| Q4 25 | $-128.5M | $39.9M | ||
| Q3 25 | $-92.7M | $27.4M | ||
| Q2 25 | $-99.9M | $7.7M | ||
| Q1 25 | $-95.2M | $-6.3M | ||
| Q4 24 | $-111.0M | $11.2M | ||
| Q3 24 | $-107.8M | $1.7M | ||
| Q2 24 | $-102.6M | $-7.5M | ||
| Q1 24 | $-115.0M | $-5.4M |
| Q4 25 | 64.6% | 71.9% | ||
| Q3 25 | 64.7% | 70.2% | ||
| Q2 25 | 65.0% | 70.1% | ||
| Q1 25 | 63.3% | 69.3% | ||
| Q4 24 | 61.6% | 71.9% | ||
| Q3 24 | 61.1% | 72.4% | ||
| Q2 24 | 59.1% | 70.6% | ||
| Q1 24 | 61.2% | 72.2% |
| Q4 25 | -43.0% | 18.6% | ||
| Q3 25 | -37.3% | 10.7% | ||
| Q2 25 | -45.9% | 3.7% | ||
| Q1 25 | -54.6% | -6.1% | ||
| Q4 24 | -62.4% | 7.5% | ||
| Q3 24 | -61.3% | 4.0% | ||
| Q2 24 | -56.8% | -3.0% | ||
| Q1 24 | -59.2% | -8.3% |
| Q4 25 | -45.7% | 18.8% | ||
| Q3 25 | -35.0% | 13.7% | ||
| Q2 25 | -43.0% | 4.0% | ||
| Q1 25 | -46.8% | -3.3% | ||
| Q4 24 | -55.0% | 5.7% | ||
| Q3 24 | -56.3% | 0.9% | ||
| Q2 24 | -57.9% | -4.3% | ||
| Q1 24 | -68.2% | -3.1% |
| Q4 25 | $-1.01 | $0.62 | ||
| Q3 25 | $-0.74 | $0.42 | ||
| Q2 25 | $-0.80 | $0.12 | ||
| Q1 25 | $-0.77 | $-0.10 | ||
| Q4 24 | $-0.90 | $0.17 | ||
| Q3 24 | $-0.88 | $0.03 | ||
| Q2 24 | $-0.84 | $-0.11 | ||
| Q1 24 | $-0.94 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $403.4M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $962.3M |
| Total Assets | $2.0B | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $403.4M | ||
| Q3 25 | $580.0M | $376.9M | ||
| Q2 25 | $629.1M | $371.1M | ||
| Q1 25 | $698.6M | $420.8M | ||
| Q4 24 | $525.5M | $384.3M | ||
| Q3 24 | $585.0M | $348.4M | ||
| Q2 24 | $933.7M | $342.7M | ||
| Q1 24 | $1.0B | $368.9M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $962.3M | ||
| Q3 25 | $-354.5M | $943.8M | ||
| Q2 25 | $-305.5M | $947.8M | ||
| Q1 25 | $-250.8M | $948.9M | ||
| Q4 24 | $-139.6M | $957.7M | ||
| Q3 24 | $-60.1M | $932.1M | ||
| Q2 24 | $-1.6M | $951.9M | ||
| Q1 24 | $68.3M | $949.1M |
| Q4 25 | $2.0B | $1.3B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.3B | $1.3B | ||
| Q4 24 | $1.5B | $1.3B | ||
| Q3 24 | $1.5B | $1.2B | ||
| Q2 24 | $1.6B | $1.2B | ||
| Q1 24 | $1.7B | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | — |
| Free Cash FlowOCF − Capex | $-54.2M | — |
| FCF MarginFCF / Revenue | -19.3% | — |
| Capex IntensityCapex / Revenue | 9.9% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | — | ||
| Q3 25 | $-35.4M | $57.4M | ||
| Q2 25 | $-60.3M | $-15.8M | ||
| Q1 25 | $-62.7M | — | ||
| Q4 24 | $-64.5M | $45.1M | ||
| Q3 24 | $-51.1M | $55.6M | ||
| Q2 24 | $-94.0M | $-9.3M | ||
| Q1 24 | $-30.3M | — |
| Q4 25 | $-54.2M | — | ||
| Q3 25 | $-45.8M | $56.8M | ||
| Q2 25 | $-65.9M | $-16.2M | ||
| Q1 25 | $-67.1M | — | ||
| Q4 24 | $-83.4M | $44.8M | ||
| Q3 24 | $-55.3M | $55.4M | ||
| Q2 24 | $-99.1M | $-9.6M | ||
| Q1 24 | $-37.2M | — |
| Q4 25 | -19.3% | — | ||
| Q3 25 | -17.3% | 28.4% | ||
| Q2 25 | -28.4% | -8.3% | ||
| Q1 25 | -33.0% | — | ||
| Q4 24 | -41.3% | 22.9% | ||
| Q3 24 | -28.9% | 29.8% | ||
| Q2 24 | -55.9% | -5.4% | ||
| Q1 24 | -22.1% | — |
| Q4 25 | 9.9% | 0.1% | ||
| Q3 25 | 3.9% | 0.3% | ||
| Q2 25 | 2.4% | 0.2% | ||
| Q1 25 | 2.2% | 0.2% | ||
| Q4 24 | 9.4% | 0.1% | ||
| Q3 24 | 2.2% | 0.1% | ||
| Q2 24 | 2.9% | 0.1% | ||
| Q1 24 | 4.1% | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 2.09× | ||
| Q2 25 | — | -2.04× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.02× | ||
| Q3 24 | — | 32.10× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
RAMP
Segment breakdown not available.
